kynurenic acid has been researched along with Bipolar Disorder in 29 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Growing evidence suggests that a dysregulation of the kynurenine pathway (KP) occurs in bipolar disorder (BD)." | 9.12 | The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites. ( Bartoli, F; Callovini, T; Carrà, G; Cavaleri, D; Cioni, RM; Crocamo, C; Misiak, B; Savitz, JB, 2021) |
| "Tryptophan catabolites (TRYCATs) are implicated in the pathophysiology of mood disorders by mediating immune-inflammation and neurodegenerative processes." | 9.12 | Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis. ( Coppens, V; De Picker, L; Giltay, EJ; Hebbrecht, K; Morrens, M; Skorobogatov, K, 2021) |
| "There has been growing scientific evidence in recent years that bipolar disorder (BD) is associated with alterations in the kynurenine (KYN) pathway." | 8.02 | Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: A preliminary study. ( Benevenuto, D; Fries, GR; Kahlon, R; Kazimi, IF; Kurian, S; Quevedo, J; Saxena, J; Saxena, K; Scaini, G; Soares, JC; Valvassori, SS; Zeni, CP, 2021) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 7.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| " Activation of indoleamine 2-3 dioxygenase following a pro-inflammatory state could reduce the amount of tryptophan converted to serotonin and increase the production of tryptophan catabolites such as kynurenic acid, an antagonist of ionotropic excitatory aminoacid receptors, whose levels are reduced in bipolar disorder." | 7.88 | Kynurenine pathway and white matter microstructure in bipolar disorder. ( Benedetti, F; Bollettini, I; Colombo, C; Grillitsch, D; Locatelli, C; Mazza, E; Myint, AM; Poletti, S; Schüetze, G; Schwarz, M, 2018) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 7.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "Inflammation-related changes in the concentrations of kynurenine-pathway metabolites occur in depression secondary to medical conditions but have not been well characterized in primary bipolar disorder (BD), with contradictory results potentially attributable to the presence or absence of psychosis and/or medication effects." | 7.81 | Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. ( Bellgowan, PS; Bodurka, J; Dantzer, R; Drevets, WC; Ford, BN; Savitz, J; Teague, TK; Victor, TA; Wurfel, BE, 2015) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 5.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "Kynurenine is an intermediate in the inflammatory cascade and can be peripherally measured to proxy inflammatory activity." | 5.46 | Tryptophan breakdown and cognition in bipolar disorder. ( Bengesser, SA; Birner, A; Dalkner, N; Fellendorf, FT; Fuchs, D; Hamm, C; Herzog-Eberhard, S; Hörmanseder, C; Kainzbauer, N; Maget, A; Mangge, H; Mansur, RB; McIntyre, RS; Moll, N; Pilz, R; Platzer, M; Queissner, R; Rauch, P; Reininghaus, EZ; Schütze, G; Schwarz, MJ; Zelzer, S, 2017) |
| "Growing evidence suggests that a dysregulation of the kynurenine pathway (KP) occurs in bipolar disorder (BD)." | 5.12 | The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites. ( Bartoli, F; Callovini, T; Carrà, G; Cavaleri, D; Cioni, RM; Crocamo, C; Misiak, B; Savitz, JB, 2021) |
| "Tryptophan catabolites (TRYCATs) are implicated in the pathophysiology of mood disorders by mediating immune-inflammation and neurodegenerative processes." | 5.12 | Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis. ( Coppens, V; De Picker, L; Giltay, EJ; Hebbrecht, K; Morrens, M; Skorobogatov, K, 2021) |
| "There has been growing scientific evidence in recent years that bipolar disorder (BD) is associated with alterations in the kynurenine (KYN) pathway." | 4.02 | Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: A preliminary study. ( Benevenuto, D; Fries, GR; Kahlon, R; Kazimi, IF; Kurian, S; Quevedo, J; Saxena, J; Saxena, K; Scaini, G; Soares, JC; Valvassori, SS; Zeni, CP, 2021) |
| "Ketamine has rapid antidepressant effects on treatment-resistant depression, but the biological mechanism underpinning this effect is less clear." | 3.88 | Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression. ( Chen, L; Li, H; Li, M; Liu, W; Ning, Y; Wang, C; Zhan, Y; Zheng, W; Zhou, Y, 2018) |
| " Activation of indoleamine 2-3 dioxygenase following a pro-inflammatory state could reduce the amount of tryptophan converted to serotonin and increase the production of tryptophan catabolites such as kynurenic acid, an antagonist of ionotropic excitatory aminoacid receptors, whose levels are reduced in bipolar disorder." | 3.88 | Kynurenine pathway and white matter microstructure in bipolar disorder. ( Benedetti, F; Bollettini, I; Colombo, C; Grillitsch, D; Locatelli, C; Mazza, E; Myint, AM; Poletti, S; Schüetze, G; Schwarz, M, 2018) |
| " Depression is hypothesized to be causally associated with an imbalance in the kynurenine pathway, with an increased metabolism down the 3-hydroxykynurenine (3HK) branch of the pathway leading to increased levels of the neurotoxic metabolite, quinolinic acid (QA), which is a putative N-methyl-d-aspartate (NMDA) receptor agonist." | 3.85 | Serum kynurenic acid is reduced in affective psychosis. ( Bliss, SA; Dantzer, R; Drevets, WC; Ford, BN; McMillin, JR; Morris, HM; Savitz, JB; Suzuki, H; Teague, TK; Wurfel, BE, 2017) |
| "Increased cytokines and kynurenic acid (KYNA) levels in cerebrospinal fluid (CSF) have been reported in patients with schizophrenia and bipolar disorder." | 3.85 | Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity. ( Bhat, M; Cannon, TD; Engberg, G; Erhardt, S; Hultman, CM; Johansson, V; Kegel, ME; Landén, M; Schuppe-Koistinen, I; Schwieler, L; Wetterberg, L, 2017) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 3.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "Inflammation-related changes in the concentrations of kynurenine-pathway metabolites occur in depression secondary to medical conditions but have not been well characterized in primary bipolar disorder (BD), with contradictory results potentially attributable to the presence or absence of psychosis and/or medication effects." | 3.81 | Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. ( Bellgowan, PS; Bodurka, J; Dantzer, R; Drevets, WC; Ford, BN; Savitz, J; Teague, TK; Victor, TA; Wurfel, BE, 2015) |
| "The kynurenine pathway metabolite kynurenic acid (KYNA), modulating glutamatergic and cholinergic neurotransmission, is increased in cerebrospinal fluid (CSF) of patients with schizophrenia or bipolar disorder type 1 with psychotic features." | 3.80 | The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. ( Backlund, L; Cichon, S; Engberg, G; Erhardt, S; Frisén, L; Landén, M; Lavebratt, C; Nikamo, P; Olsson, S; Osby, U; Priebe, L; Schalling, M; Sellgren, C; Träskman-Bendz, L; Vawter, MP, 2014) |
| "The upregulation of the initiating step of the kynurenine pathway was demonstrated in postmortem anterior cingulated cortex from individuals with schizophrenia and bipolar disorder." | 3.74 | Tryptophan breakdown pathway in bipolar mania. ( Kim, YK; Leonard, BE; Myint, AM; Park, SH; Scharpé, S; Steinbusch, HW; Verkerk, R, 2007) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 1.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| "Kynurenine is an intermediate in the inflammatory cascade and can be peripherally measured to proxy inflammatory activity." | 1.46 | Tryptophan breakdown and cognition in bipolar disorder. ( Bengesser, SA; Birner, A; Dalkner, N; Fellendorf, FT; Fuchs, D; Hamm, C; Herzog-Eberhard, S; Hörmanseder, C; Kainzbauer, N; Maget, A; Mangge, H; Mansur, RB; McIntyre, RS; Moll, N; Pilz, R; Platzer, M; Queissner, R; Rauch, P; Reininghaus, EZ; Schütze, G; Schwarz, MJ; Zelzer, S, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (6.90) | 29.6817 |
| 2010's | 16 (55.17) | 24.3611 |
| 2020's | 11 (37.93) | 2.80 |
| Authors | Studies |
|---|---|
| Hebbrecht, K | 2 |
| Morrens, M | 2 |
| Giltay, EJ | 2 |
| van Nuijs, ALN | 1 |
| Sabbe, B | 1 |
| van den Ameele, S | 1 |
| Sales, PMG | 3 |
| Schrage, E | 3 |
| Coico, R | 3 |
| Pato, M | 3 |
| Kadriu, B | 1 |
| Farmer, CA | 1 |
| Yuan, P | 1 |
| Park, LT | 1 |
| Deng, ZD | 1 |
| Moaddel, R | 1 |
| Henter, ID | 1 |
| Shovestul, B | 1 |
| Ballard, ED | 1 |
| Kraus, C | 1 |
| Gold, PW | 1 |
| Machado-Vieira, R | 1 |
| Zarate, CA | 1 |
| Bartoli, F | 2 |
| Misiak, B | 1 |
| Callovini, T | 2 |
| Cavaleri, D | 2 |
| Cioni, RM | 2 |
| Crocamo, C | 2 |
| Savitz, JB | 2 |
| Carrà, G | 2 |
| Benevenuto, D | 1 |
| Saxena, K | 1 |
| Fries, GR | 1 |
| Valvassori, SS | 1 |
| Kahlon, R | 1 |
| Saxena, J | 1 |
| Kurian, S | 1 |
| Zeni, CP | 1 |
| Kazimi, IF | 1 |
| Scaini, G | 1 |
| Soares, JC | 2 |
| Quevedo, J | 2 |
| Marx, W | 1 |
| McGuinness, AJ | 1 |
| Rocks, T | 1 |
| Ruusunen, A | 1 |
| Cleminson, J | 1 |
| Walker, AJ | 1 |
| Gomes-da-Costa, S | 1 |
| Lane, M | 1 |
| Sanches, M | 1 |
| Diaz, AP | 1 |
| Tseng, PT | 1 |
| Lin, PY | 1 |
| Berk, M | 1 |
| Clarke, G | 1 |
| O'Neil, A | 1 |
| Jacka, F | 1 |
| Stubbs, B | 1 |
| Carvalho, AF | 1 |
| Fernandes, BS | 1 |
| Trepci, A | 1 |
| Sellgren, CM | 4 |
| Pålsson, E | 1 |
| Brundin, L | 1 |
| Khanlarkhani, N | 1 |
| Schwieler, L | 5 |
| Landén, M | 9 |
| Erhardt, S | 9 |
| Imbeault, S | 1 |
| Larsson, MK | 1 |
| Oliveros, A | 1 |
| Nilsson, IAK | 1 |
| Codeluppi, S | 1 |
| Orhan, F | 1 |
| Bhat, M | 3 |
| Tufvesson-Alm, M | 1 |
| Gracias, J | 2 |
| Kegel, ME | 3 |
| Zheng, Y | 1 |
| Faka, A | 1 |
| Svedberg, M | 1 |
| Powell, SB | 1 |
| Caldwell, S | 1 |
| Kamenski, ME | 1 |
| Vawter, MP | 3 |
| Schulmann, A | 1 |
| Goiny, M | 1 |
| Svensson, CI | 2 |
| Hökfelt, T | 1 |
| Schalling, M | 3 |
| Cervenka, S | 1 |
| Choi, DS | 1 |
| Engberg, G | 8 |
| Skorobogatov, K | 1 |
| Coppens, V | 1 |
| De Picker, L | 1 |
| Wurfel, BE | 3 |
| Drevets, WC | 3 |
| Bliss, SA | 1 |
| McMillin, JR | 1 |
| Suzuki, H | 1 |
| Ford, BN | 2 |
| Morris, HM | 1 |
| Teague, TK | 3 |
| Dantzer, R | 3 |
| Platzer, M | 2 |
| Dalkner, N | 2 |
| Fellendorf, FT | 2 |
| Birner, A | 2 |
| Bengesser, SA | 2 |
| Queissner, R | 2 |
| Kainzbauer, N | 1 |
| Pilz, R | 2 |
| Herzog-Eberhard, S | 2 |
| Hamm, C | 2 |
| Hörmanseder, C | 1 |
| Maget, A | 2 |
| Rauch, P | 2 |
| Mangge, H | 2 |
| Fuchs, D | 2 |
| Zelzer, S | 2 |
| Schütze, G | 2 |
| Moll, N | 2 |
| Schwarz, MJ | 1 |
| Mansur, RB | 1 |
| McIntyre, RS | 1 |
| Reininghaus, EZ | 2 |
| Meier, TB | 1 |
| Mueller, SC | 1 |
| Bodurka, J | 2 |
| Savitz, J | 2 |
| Zhou, Y | 1 |
| Zheng, W | 1 |
| Liu, W | 1 |
| Wang, C | 1 |
| Zhan, Y | 1 |
| Li, H | 1 |
| Chen, L | 1 |
| Li, M | 1 |
| Ning, Y | 1 |
| Jungholm, O | 1 |
| Perlis, RH | 1 |
| Johansson, V | 2 |
| Kegel, M | 1 |
| Blennow, K | 1 |
| Zetterberg, H | 1 |
| Cannon, TD | 2 |
| Wetterberg, L | 2 |
| Hultman, CM | 3 |
| Lavebratt, C | 1 |
| Olsson, S | 2 |
| Backlund, L | 2 |
| Frisén, L | 1 |
| Sellgren, C | 2 |
| Priebe, L | 1 |
| Nikamo, P | 1 |
| Träskman-Bendz, L | 1 |
| Cichon, S | 1 |
| Osby, U | 1 |
| Johansson, AS | 1 |
| Owe-Larsson, B | 1 |
| Asp, L | 1 |
| Kocki, T | 1 |
| Adler, M | 1 |
| Hetta, J | 1 |
| Gardner, R | 1 |
| Lundkvist, GB | 1 |
| Urbanska, EM | 1 |
| Karlsson, H | 1 |
| Victor, TA | 1 |
| Bellgowan, PS | 1 |
| Fukuda, K | 1 |
| Bergen, SE | 1 |
| Ekman, CJ | 1 |
| Larsson, M | 1 |
| Sullivan, PF | 1 |
| Sklar, P | 1 |
| Smoller, JW | 1 |
| Magnusson, PK | 1 |
| Walther-Jallow, L | 1 |
| Lichtenstein, P | 1 |
| Poletti, S | 1 |
| Myint, AM | 2 |
| Schüetze, G | 1 |
| Bollettini, I | 1 |
| Mazza, E | 1 |
| Grillitsch, D | 1 |
| Locatelli, C | 1 |
| Schwarz, M | 2 |
| Colombo, C | 1 |
| Benedetti, F | 1 |
| Fornaro, M | 1 |
| Nardi, AE | 1 |
| De Berardis, D | 1 |
| Carta, MG | 1 |
| Schuppe-Koistinen, I | 1 |
| Reininghaus, B | 1 |
| Kapfhammer, HP | 1 |
| Olsson, SK | 2 |
| Samuelsson, M | 1 |
| Saetre, P | 1 |
| Lindström, L | 1 |
| Jönsson, EG | 1 |
| Nordin, C | 1 |
| Miller, CL | 1 |
| Llenos, IC | 1 |
| Dulay, JR | 1 |
| Weis, S | 1 |
| Kim, YK | 1 |
| Verkerk, R | 1 |
| Park, SH | 1 |
| Scharpé, S | 1 |
| Steinbusch, HW | 1 |
| Leonard, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist[NCT00088699] | Phase 1/Phase 2 | 67 participants (Actual) | Interventional | 2004-07-26 | Completed | ||
| Vortioxetine Monotherapy for Major Depressive Disorder in Type 2 Diabetes: Role of Inflammation, Kynurenine Pathway, and Structural and Functional Brain Connectivity as Biomarkers[NCT03580967] | Phase 4 | 0 participants (Actual) | Interventional | 2019-07-01 | Withdrawn (stopped due to COVID-19 Pandemic interfered with Pt recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Baseline
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 1.17 |
| Placebo - Healthy Volunteers | 1.48 |
| Ketamine - MDD Patients | 33.83 |
| Placebo - MDD Patients | 31.82 |
Antidepressant effects were assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS). It is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes. Higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. (NCT00088699)
Timeframe: Day 1
| Intervention | units on a scale (Mean) |
|---|---|
| Ketamine - Healthy Volunteers | 2.45 |
| Placebo - Healthy Volunteers | 0.67 |
| Ketamine - MDD Patients | 23.73 |
| Placebo - MDD Patients | 30.68 |
5 reviews available for kynurenic acid and Bipolar Disorder
| Article | Year |
|---|---|
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
Linking nervous and immune systems in psychiatric illness: A meta-analysis of the kynurenine pathway.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Immune System; Kynurenic Acid; Kynurenine; Try | 2023 |
The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites.
Topics: Adult; Bipolar Disorder; Humans; Kynurenic Acid; Kynurenine; Observational Studies as Topic; Quinoli | 2021 |
The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies.
Topics: Bipolar Disorder; Depressive Disorder, Major; Humans; Kynurenic Acid; Kynurenine; Schizophrenia | 2021 |
Tryptophan Catabolites in Bipolar Disorder: A Meta-Analysis.
Topics: Bipolar Disorder; Depression; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptophan | 2021 |
Experimental drugs for bipolar psychosis.
Topics: Animals; Antipsychotic Agents; Bipolar Disorder; Drug Design; Humans; Kynurenic Acid; Lithium Compou | 2016 |
24 other studies available for kynurenic acid and Bipolar Disorder
| Article | Year |
|---|---|
The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder.
Topics: Bipolar Disorder; Cognitive Dysfunction; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptopha | 2022 |
The kynurenine pathway and bipolar disorder: intersection of the monoaminergic and glutamatergic systems and immune response.
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Humans; Immunity; Kynurenic Acid; Kynurenine; Middle Aged | 2021 |
Alterations in plasma kynurenine pathway metabolites in children and adolescents with bipolar disorder and unaffected offspring of bipolar parents: A preliminary study.
Topics: Adolescent; Adult; Bipolar Disorder; Child; Humans; Kynurenic Acid; Kynurenine; Parents; Tryptophan | 2021 |
Central levels of tryptophan metabolites in subjects with bipolar disorder.
Topics: Bipolar Disorder; Chromatography, Liquid; Humans; Kynurenic Acid; Kynurenine; Tandem Mass Spectromet | 2021 |
GRK3 deficiency elicits brain immune activation and psychosis.
Topics: Animals; Bipolar Disorder; Brain; Kynurenic Acid; Mice; Psychotic Disorders; Schizophrenia | 2021 |
The kynurenine pathway in schizophrenia and other mental disorders: Insight from meta-analyses on the peripheral blood levels of tryptophan and related metabolites.
Topics: Bipolar Disorder; Humans; Kynurenic Acid; Kynurenine; Schizophrenia; Tryptophan | 2021 |
Serum kynurenic acid is reduced in affective psychosis.
Topics: Adult; Affective Disorders, Psychotic; Bipolar Disorder; Corpus Striatum; Cytokines; Depression; Dep | 2017 |
Tryptophan breakdown and cognition in bipolar disorder.
Topics: Adult; Bipolar Disorder; Case-Control Studies; Cognition; Female; Humans; Kynurenic Acid; Kynurenine | 2017 |
Kynurenic acid is reduced in females and oral contraceptive users: Implications for depression.
Topics: Adult; Bipolar Disorder; C-Reactive Protein; Contraceptives, Oral, Hormonal; Cross-Sectional Studies | 2018 |
Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression.
Topics: Administration, Intravenous; Adult; Antidepressive Agents; Bipolar Disorder; China; Chromatography, | 2018 |
Peripheral and central levels of kynurenic acid in bipolar disorder subjects and healthy controls.
Topics: Adult; Bipolar Disorder; Chromatography, High Pressure Liquid; Depression; Female; Humans; Kynurenic | 2019 |
Twin study shows association between monocyte chemoattractant protein-1 and kynurenic acid in cerebrospinal fluid.
Topics: Adult; Aged; Bipolar Disorder; Chemokine CCL2; Cohort Studies; Female; Humans; Kynurenic Acid; Male; | 2020 |
The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression.
Topics: Adult; Aged; Alleles; Bipolar Disorder; Case-Control Studies; Cell Line; Female; Gene Expression; Ge | 2014 |
Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine.
Topics: Adult; Bipolar Disorder; Cells, Cultured; Cytokines; Female; Fibroblasts; Gene Expression Regulation | 2013 |
Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder.
Topics: Adult; Amygdala; Bipolar Disorder; Female; Hippocampus; Humans; Kynurenic Acid; Kynurenine; Male; Mi | 2015 |
Integrated theory to unify status among schizophrenia and manic depressive illness.
Topics: 5-Hydroxytryptophan; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Biopterins; Bipolar Dis | 2015 |
A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Brain; Chromosomes, Human, Pair 1; Cognition Disorders; Cognitive Dys | 2016 |
Kynurenine pathway and white matter microstructure in bipolar disorder.
Topics: Adult; Bipolar Disorder; Diffusion Tensor Imaging; Female; Humans; Hydroxyindoleacetic Acid; Kynuren | 2018 |
Kynurenic acid and psychotic symptoms and personality traits in twins with psychiatric morbidity.
Topics: Bipolar Disorder; Female; Humans; Interleukin-6; Interleukin-8; Kynurenic Acid; Male; Middle Aged; P | 2017 |
Increased breakdown of kynurenine towards its neurotoxic branch in bipolar disorder.
Topics: Adult; Bipolar Disorder; Brain; Case-Control Studies; Cognition; Depression; Female; Humans; Inflamm | 2017 |
Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.
Topics: Adult; Age Factors; Bipolar Disorder; Case-Control Studies; Chromatography, High Pressure Liquid; Di | 2010 |
Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Chromatography, High Pressure Liquid; Female; Humans; Kyn | 2012 |
Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.
Topics: Adult; Analysis of Variance; Bipolar Disorder; Chromatography, High Pressure Liquid; Demography; Dep | 2006 |
Tryptophan breakdown pathway in bipolar mania.
Topics: Adult; Aspartic Acid; Bipolar Disorder; Brief Psychiatric Rating Scale; Female; Gyrus Cinguli; Human | 2007 |